|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Zhou BB and Elledge SJ: The DNA damage
response: Putting checkouts in perspective. Nature. 408:433–439.
2000. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hu ZB, Ma HX, Tan W, et al: The research
between genetic susceptibility to lung cancer and p73 gene
polymorphism. Chin J Epidemiol. 26:106–109. 2005.
|
|
4
|
Cheng Z, Wang W, Song YN, Kang Y and Xia
J: hoGG1, p53 genes and smoking interactions are associated with
the development of lung cancer. Asian Pac J Cancer Prev.
13:1803–1808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kaghad M, Bonnet H, Yang A, Creancier L,
Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, et al:
Monoallelically expressed gene related to p53 at lp36, a region
frequently deleted in neuroblastoma and other human cancers. Cell.
90:809–819. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Melino G, De Laurenzi V and Vousden KH:
p73: Friend or foe in tumorigenesis. Nat Rev Cancer. 2:605–615.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Peters MA, Janer M, Kolb S, Jarvik GP,
Ostrander EA and Stanford JL: Germline mutations in the p73 gene do
not predispose to familial prostate-brain cancer. Prostate.
48:292–296. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ryan BM, Mcmanus R, Daly JS, Carton E,
Keeling PW, Reynolds JV and Kelleher D: A common p73 polymorphism
is associated with a reduced incidence of oesophageal carcinoma. Br
J Cancer. 85:1499–1503. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Huang XE, Hamajima N, Katsuda N, Matsuo K,
Hirose K, Mizutani M, Iwata H, Miura S, Xiang J, Tokudome S and
Tajima K: Association of p53 codon Arg72pro and p73 G4C14-to-A4T14
at exon 2 genetic polymorphisms with the risk of Japanese breast
cancer. Breast Cancer. 10:307–311. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li G, Sturgis EM, Wang LE, Chamberlain RM,
Amos CI, Spitz MR, El-Naggar AK, Hong WK and Wei Q: Association of
a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of squamous cell
carcinoma of the head and neck. Carcinogenesis. 25:1911–1916. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lee KE, Hong YS, Kim BG, Kim NY, Lee KM,
Kwak JY and Roh MS: p73 G4C14 to A4T14 polymorphism is associated
with colorectal cancer risk and survival. World J Gastroenterol.
16:4448–4454. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Niwa Y, Hamajima N, Atsuta Y, Yamamoto K,
Tamakoshi A, Saito T, Hirose K, Nakanishi T, Nawa A, Kuzuya K and
Tajima K: Genetic polymorphisms of p73 G4C14-to-A4T14 at exon 2 and
p53 Arg72Pro and the risk of cervical cancer in Japanese. Cancer
Lett. 205:55–60. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pfeifer D, Arbman G and Sun XF:
Polymorphism of the p73 gene in relation to colorectal cancer risk
and survival. Carcinogenesis. 26:103–107. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Niwa Y, Hirose K, Matsuo K, Tajima K,
Ikoma Y, Nakanishi T, Nawa A, Kuzuya K, Tamakoshi A and Hamajima N:
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 and p53
Arg72Pro polymorphism with the risk of endometrial cancer in
Japanese subjects. Cancer Lett. 219:183–190. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li G, Wang LE, Chamberlain RM, Amos CI,
Spitz MR and Wei Q: p73 G4C14-to-A4T14 polymorphism and risk of
lung cancer. Cancer Res. 64:6863–6866. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hu Z, Miao X, Ma H, Tan W, Wang X, Lu D,
Wei Q, Lin D and Shen H: Dinucleotide polymorphism of p73 gene is
associated with a reduced risk of lung cancer in a Chinese
population. Int J Cancer. 114:455–460. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang X, Li X, Wu Z, Lin F and Zhou H: The
p73 G4C14-to-A4T14 polymorphism is associated with risk of lung
cancer in the Han Nationality of North China. Mol Carcinog.
52:387–391. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ozaki T and Nakagawara A: p73, a
sophisticated p53 family member in the cancer world. Cancer Sci.
96:729–737. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Levrero M, De Laurenzi V, Costanzo A, Gong
J, Melino G and Wang JY: Structure, function and regulation of p63
and p73. Cell Death Differ. 6:1146–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zeng X, Chen L, Jost CA, Maya R, Keller D,
Wang X, Kaelin WG Jr, Oren M, Chen J and Lu H: MDM2 suppresses p73
function without promoting p73 degradation. Mol Cell Biol.
19:3257–3266. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lundgren K, de Oca Luna R Montes, McNeill
YB, Emerick EP, Spencer B, Barfield CR, Lozano G, Rosenberg MP and
Finlay CA: Targeted expression of MDM2 uncouples S phase from
mitosis and inhibits mammary gland development independent of p53.
Genes Dev. 11:714–725. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bond GL, Hu W, Bond EE, Robins H, Lutzker
SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A
single nucleotide polymorphism in the MDM2 promoter attenuates the
p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bougeard G, Baert-Desurmont S, Tournier I,
Vasseur S, Martin C, Brugieres L, Chompret A, Bressac-de Paillerets
B, Stoppa-Lyonnet D, Bonaiti-Pellie C and Frebourg T: Impact of the
MDM2 SNP309 and p53 Arg72Pro polymorphism on age tumor onset in
Li-Fraumeni syndrome. J Med Genet. 43:531–533. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheng H, Xie L, Hu WJ, et al: Detection of
the MDM2 SNP309 by QRT-PCR. J Clin Oncol. 16:577–581. 2011.
|
|
25
|
Wang SS, Guo HY, Dong LL, Zhu XQ, Ma L, Li
W and Tang JX: Association between a p73 gene polymorphism and
genetic susceptibility to non-small cell lung cancer in the South
of China. Asian Pac J Cancer Prev. 15:10387–19391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu J, Jiang J, Zhou W and Chen X: The
potential tumor suppressor p73 differently regulates cellular p53
target genes. Cancer Res. 58:5061–5065. 1998.PubMed/NCBI
|
|
27
|
Jost CA, Marin MC and Kaelin WG Jr: p73 is
a simian [correction of human] p53-related protein that can induce
apoptosis. Nature. 389:191–194. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Hamajima N, Matsuo K, Suzuki T, Nakamura
T, Matsuura A, Hatooka S, Shinoda M, Kodera Y, Yamamura Y, Hirai T,
et al: No association of p73 G4C14-to-A4T14 at exon 2 and p53
Arg72Pro polymorphism with the risk of digestive tract cancers in
Japanese. Cancer Lett. 181:81–85. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choi JE, Kang HG, Chae MH, Kim EJ, Lee WK,
Cha SI, Kim CH, Jung TH and Park JY: No association between p73
G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean
population. Biochem Genet. 44:543–550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bond GL, Hirshfield KM, Kirchhoff T, Alexe
G, Bond EE, Robins H, Bartel F, Taubert H, Wuerl P, Hait W, et al:
MDM2 SNP309 accelerates tumor formation in a gender-specific and
hormone-dependent manner. Cancer Res. 66:5104–5110. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jun HJ, Park SH, Lee WK, Choi JE, Jang JS,
Kim EJ, Cha SI, Kim DS, Kam S, Kim CH, et al: Combined effects off
p73 and MDM2 polymorphisms on the risk of lung cancer. Mol
Carcinog. 46:100–105. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang X, Miao X, Guo Y, Tan W, Zhou Y, Sun
T, Wang Y and Lin D: Genetic polymorphisms in cell cycle regulatory
genes MDM2 and TP53 are associated with susceptibility to lung
cancer. Hum Mutat. 27:110–117. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J,
Jin G, Liu J, Wang X, Wei Q and Shen H: Polymorphisms in the MDM2
promoter and risk of breast cancer: A case-control analysis in a
Chinese population. Cancer Lett. 240:261–267. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Campbell IG, Eccles DM and Choong DY: No
association of the MDM2 SNP309 polymorphism with risk of breast or
ovarian cancer. Cancer Lett. 240:195–197. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu Z, Ma H, Lu D, Qian J, Zhou J, Chen Y,
Xu L, Wang X, Wei Q and Shen H: Genetic variants in the MDM2
promoter and lung cancer risk in a Chinese population. Int J
Cancer. 118:1275–1278. 2006. View Article : Google Scholar : PubMed/NCBI
|
